Opko Health (OPK) Stock Soaring on Earnings Beat
NEW YORK (TheStreet) -- Opko Health (OPK) - Get Report stock is up by 5.03% to $10.45 in late morning trading on Tuesday, after the company's 2015 third quarter earnings results beat analysts' expectations.
After the market close on Tuesday, the bio-pharmaceutical and diagnostics company reported earnings of 25 cents per share.
Revenue increased to $143 million, up from $19.8 million for the year-ago period.
Analysts were expecting the company to report a loss of 1 cent per share on revenue of $132.99 million.
"OPKO has already achieved numerous important milestones during 2015," CEO Phillip Frost said in a statement. "We believe that the Pfizer (PFE) transaction for hGH-CTP and the acquisitions of EirGen and Bio-Reference Laboratories have had a positive impact on our financial operations and will provide significant revenue opportunities and an expanded commercial platform for us going forward."
Separately, TheStreet Ratings team rates OPKO HEALTH INC as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:
We rate OPKO HEALTH INC (OPK) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.
You can view the full analysis from the report here: OPK
data by
Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.